TABLE 2.
Anterior chamber flare before and 1 day and 1 month after each intravitreal bevacizumab injection in group of women and men.
| Women | Men | p | |||||
|---|---|---|---|---|---|---|---|
| n° | Mean | SD | n | Median | SD | ||
| Age | 28 | 67.71 | 11.25 | 20 | 69.55 | 7.94 | 0.565 |
| Before treatment | 28 | 7.34 | 3.55 | 20 | 7.75 | 3.31 | 0.579 |
| 1 day after 1st injection | 27 | 7.21 | 3.51 | 20 | 7.52 | 2.75 | 0.383 |
| 30 days after 1st injection | 27 | 7.01 | 3.18 | 19 | 7.15 | 3.46 | 0.647 |
| 1 day after 2nd injection | 27 | 8.26 | 3.04 | 20 | 7.72 | 3.16 | 0.583 |
| 30 days after 2nd injection | 25 | 7.47 | 3.20 | 16 | 8.16 | 5.59 | 0.936 |
| 1 day after 3rd injection | 24 | 7.41 | 3.30 | 14 | 7.93 | 4.79 | 0.987 |
| 30 days after 3rd injection | 28 | 6.73 | 2.78 | 20 | 7.33 | 2.42 | 0.310 |
SD, standard deviation; p, p value: p-values estimated with Mann-Whitney U test.